Our pipeline is led by RSO-021, which is currently being evaluated in a Phase 2 clinical trial in mesothelioma, and as a combination therapy in metastatic breast cancer, metastatic ovarian cancer, and non-small cell lung cancer.

 

Our second-generation PRX3 inhibitor, RSO-023, is in preclinical development to evaluate it as a systemic drug for all solid tumors.